hydrALAZINE HCl Tablets 10 mg Recalled for Failed Impurity Specifications
The Harvard Drug Group is recalling hydrALAZINE HCl Tablets, USP, 10 mg due to failed impurity and degradation specifications detected during routine stability testing. The recall affects 5,953 cartons distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall involving failed stability specifications detected during routine testing. No illnesses, injuries, or adverse events are reported in the source text. The hazard is identified through quality control testing rather than real-world harm, making this a precautionary recall that meets the Moderate severity threshold for Class II recalls without reported adverse outcomes.
Plain-English summary
The Harvard Drug Group is recalling hydrALAZINE HCl Tablets, USP, 10 mg (NDC # 0904-6440-61) distributed by MAJOR PHARMACEUTICALS. The recall involves 5,953 cartons containing 100 tablets per carton in 10x10 blister pack configurations.
The recall was initiated due to out-of-specification results obtained during routine stability testing for impurities and degradation. This indicates that the product did not meet established quality standards for chemical purity and stability.
The affected lots are T03755 and T03756 with an expiration date of 03/2023. The product was distributed nationwide within the USA as a prescription medication.
Patients currently taking this medication should consult their healthcare provider or pharmacist immediately regarding this recall.
The recalled product
- Product
- hydrALAZINE HCl Tablets, USP, 10 mg, 100 Tablets per carton (10x10 blister packs), Rx only, Distributed by: MAJOR PHARMACEUTICALS, Livonia, MI 48152 USA. NDC # 0904-6440-61
- Manufacturer
- The Harvard Drug Group
- Hazard
- impurity-degradation
- quality-specifications
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot #: T03755
- T03756
- Exp. Date 03/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27